Author:
Perez Alejandro,Huse Jason T.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Neuroscience
Reference30 articles.
1. •• Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844–56. https://doi.org/10.1111/bpa.12832. This article details recommendations for the upcoming WHO 2021 Classification of CNS Neoplasms, including refined diagnostic classes and conversion to Arabic numerals for grading.
2. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–8. https://doi.org/10.1007/s00401-020-02127-9.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D et al. WHO Classification of Tumors of the Central Nervous System. World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer; 2016.
4. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66–77. https://doi.org/10.1093/neuonc/nox132.
5. • Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519–28. https://doi.org/10.1093/neuonc/noz124. This article identifies CDKN2A deletion as a robust prognostic marker in IDH-mutant astrocytoma.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献